Humoral immunity to HIV-1: neutralisation and antibody effector functions

Trends in Microbiology

Volumn 16, Issue 12, 2008, Pages 596-604

  Willey, Suzanne ^a   Aasa Chapman, Marlén M I ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

COMPLEMENT ACTIVATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANTIBODY FORMATION; COMPLEMENT ACTIVATION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS; RECEPTORS, FC;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 56649083541     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2008.08.008     Document Type: Review

References (101)

1. Barre-Sinoussi F., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220 (1983) 868-871
2. Gallo R.C., et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224 (1984) 500-503
3. Weiss R.A., et al. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 316 (1985) 69-72
4. Robert-Guroff M., et al. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 316 (1985) 72-74
5. Richman D.D., et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4144-4149
6. Wei X., et al. Antibody neutralization and escape by HIV-1. Nature 422 (2003) 307-312
7. Frost S.D., et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18514-18519
8. Mascola J.R. Defining the protective antibody response for HIV-1. Curr. Mol. Med. 3 (2003) 209-216
9. Taylor B.S., et al. The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 358 (2008) 1590-1602
10. Gaschen B., et al. Diversity considerations in HIV-1 vaccine selection. Science 296 (2002) 2354-2360
11. Burton D.R., et al. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 14943-14948
12. Srivastava I.K., et al. Role of neutralizing antibodies in protective immunity against HIV. Hum. Vaccin. 1 (2005) 45-60
13. Aasa-Chapman M.M., et al. Development of the antibody response in acute HIV-1 infection. AIDS 18 (2004) 371-381
14. Gray E.S., et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 81 (2007) 6187-6196
15. Li Y., et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13 (2007) 1032-1034
16. Derdeyn C.A., et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303 (2004) 2019-2022
17. Simon V., and Ho D.D. HIV-1 dynamics in vivo: implications for therapy. Nat. Rev. Microbiol. 1 (2003) 181-190
18. Lemey P., et al. HIV evolutionary dynamics within and among hosts. AIDS Rev. 8 (2006) 125-140
19. Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat. Rev. Immunol. 5 (2005) 783-792
20. Keele B.F., et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 7552-7557
21. Zhang L., et al. Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination. J. Virol. 78 (2004) 5520-5522
22. Trkola A., et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11 (2005) 615-622
23. Smith D.M., et al. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology 355 (2006) 1-5
24. Piantadosi A., et al. Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog. 3 (2007) e177
25. Wyatt R., and Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280 (1998) 1884-1888
26. Zanetti G., et al. Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog. 2 (2006) e83
27. Zhu P., et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441 (2006) 847-852
28. Parren P.W., et al. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J. Virol. 72 (1998) 3512-3519
29. Yang X., et al. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J. Virol. 79 (2005) 12132-12147
30. Nyambi P.N., et al. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J. Virol. 74 (2000) 7096-7107
31. Herrera C., et al. Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J. Virol. 77 (2003) 1084-1091
32. Poignard P., et al. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 77 (2003) 353-365
33. Moore P.L., et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 80 (2006) 2515-2528
34. Crooks E.T., et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366 (2007) 245-262
35. Moore J.P., et al. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250 (1990) 1139-1142
36. Burton D.R. Structural biology: images from the surface of HIV. Nature 441 (2006) 817-818
37. Parren P.W., et al. HIV-1 antibody-debris or virion?. Nat. Med. 3 (1997) 366-367
38. Moore J.P., and Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70 (1996) 1863-1872
39. Wyatt R., et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393 (1998) 705-711
40. Burrer R., et al. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41. Virology 333 (2005) 102-113
41. Li Y., et al. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J. Virol. 82 (2008) 638-651
42. Huang C.C., et al. Structure of a V3-containing HIV-1 gp120 core. Science 310 (2005) 1025-1028
43. Moore P.L., et al. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J. Virol. 82 (2008) 1860-1869
44. Labrijn A.F., et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77 (2003) 10557-10565
45. Decker J.M., et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201 (2005) 1407-1419
46. McKnight A., and Aasa-Chapman M.M. Clade specific neutralising vaccines for HIV: an appropriate target?. Curr. HIV Res. 5 (2007) 554-560
47. Stoiber H., et al. Complement-HIV interactions during all steps of viral pathogenesis. Vaccine 26 (2008) 3046-3054
48. Susal C., et al. Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120. Blood 87 (1996) 2329-2336
49. Ebenbichler C.F., et al. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J. Exp. Med. 174 (1991) 1417-1424
50. Spear G.T., et al. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J. Virol. 67 (1993) 53-59
51. Sullivan B.L., et al. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. J. Immunol. 157 (1996) 1791-1798
52. Huber M., et al. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med. 3 (2006) e441
53. Sullivan B.L., et al. Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism. Virology 248 (1998) 173-181
54. Blue C.E., et al. The relevance of complement to virus biology. Virology 319 (2004) 176-184
55. Saifuddin M., et al. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J. Exp. Med. 182 (1995) 501-509
56. Stoiber H., et al. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J. Exp. Med. 183 (1996) 307-310
57. Marschang P., et al. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur. J. Immunol. 25 (1995) 285-290
58. Aasa-Chapman M.M., et al. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J. Virol. 79 (2005) 2823-2830
59. Sullivan N.J. Antibody-mediated enhancement of viral disease. Curr. Top. Microbiol. Immunol. 260 (2001) 145-169
60. Beck Z., et al. Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development. Vaccine 26 (2008) 3078-3085
61. Willey, S. et al. (2008) Role of complement in early HIV infection: a double-edged sword? AIDS Res. Hum. Retroviruses (in press)
62. Robinson Jr. W.E., et al. Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology 175 (1990) 600-604
63. Prohaszka Z., et al. Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. AIDS 11 (1997) 949-958
64. Bajtay Z., et al. Cutting edge: productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18). J. Immunol. 173 (2004) 4775-4778
65. Lund O., et al. Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection. J. Virol. 69 (1995) 2393-2400
66. Robinson W.E. Mechanism for complement-mediated, antibody-dependent enhancement of human immunodeficiency virus type 1 infection in MT2 cells is enhanced entry through CD4, CD21, and CXCR4 chemokine receptors. Viral Immunol. 19 (2006) 434-447
67. Robinson Jr. W.E., et al. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J. Virol. 64 (1990) 5301-5305
68. Kacani L., et al. Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J. Virol. 74 (2000) 7997-8002
69. Ho J., et al. Role for CD21 in the establishment of an extracellular HIV reservoir in lymphoid tissues. J. Immunol. 178 (2007) 6968-6974
70. Smith-Franklin B.A., et al. Follicular dendritic cells and the persistence of HIV infectivity: the role of antibodies and Fcgamma receptors. J. Immunol. 168 (2002) 2408-2414
71. Heath S.L., et al. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377 (1995) 740-744
72. Smith B.A., et al. Persistence of infectious HIV on follicular dendritic cells. J. Immunol. 166 (2001) 690-696
73. Keele B.F., et al. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J. Virol. 82 (2008) 5548-5561
74. Moir S., et al. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J. Exp. Med. 192 (2000) 637-646
75. Doepper S., et al. B cell-mediated infection of stimulated and unstimulated autologous T lymphocytes with HIV-1: role of complement. Immunobiology 202 (2000) 293-305
76. Banki Z., et al. Factor I-mediated processing of complement fragments on HIV immune complexes targets HIV to CR2-expressing B cells and facilitates B cell-mediated transmission of opsonized HIV to T cells. J. Immunol. 177 (2006) 3469-3476
77. Malaspina A., et al. Human immunodeficiency virus type 1 bound to B cells: relationship to virus replicating in CD4+ T cells and circulating in plasma. J. Virol. 76 (2002) 8855-8863
78. Cavrois M., et al. The Achilles heel of the Trojan horse model of HIV-1 trans-infection. PLoS Pathog. 4 (2008) e1000051
79. Pruenster M., et al. C-type lectin-independent interaction of complement opsonized HIV with monocyte-derived dendritic cells. Eur. J. Immunol. 35 (2005) 2691-2698
80. Bouhlal H., et al. Opsonization of HIV with complement enhances infection of dendritic cells and viral transfer to CD4 T cells in a CR3 and DC-SIGN-dependent manner. J. Immunol. 178 (2007) 1086-1095
81. Connick E., et al. HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res. Hum. Retroviruses 12 (1996) 1129-1140
82. Forthal D.N., et al. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 75 (2001) 6953-6961
83. Nixon D.F., et al. Cellular and humoral antigenic epitopes in HIV and SIV. Immunology 76 (1992) 515-534
84. Ruppach H., et al. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes. J. Virol. 74 (2000) 5403-5411
85. Holl V., et al. Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages. J. Immunol. 173 (2004) 6274-6283
86. Holl V., et al. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 107 (2006) 4466-4474
87. Wilflingseder D., et al. IgG opsonization of HIV impedes provirus formation in and infection of dendritic cells and subsequent long-term transfer to T cells. J. Immunol. 178 (2007) 7840-7848
88. Hessell A.J., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449 (2007) 101-104
89. Takeda A., et al. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242 (1988) 580-583
90. Homsy J., et al. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J. Virol. 64 (1990) 1437-1440
91. Kozlowski P.A., et al. High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons. Masking by IgG. J. Immunol. 154 (1995) 6163-6173
92. Brouwer K.C., et al. Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection. AIDS 18 (2004) 1187-1194
93. Forthal D.N., et al. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178 (2007) 6596-6603
94. Forthal D.N., et al. FcgammaRIIa genotype predicts progression of HIV infection. J. Immunol. 179 (2007) 7916-7923
95. Forthal D.N., et al. Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res. Hum. Retroviruses 17 (2001) 553-561
96. Ahmad R., et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J. Clin. Immunol. 21 (2001) 227-233
97. Subbramanian R.A., et al. Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients. J. Clin. Microbiol. 40 (2002) 2141-2146
98. Zhou T., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 (2007) 732-737
99. Frey G., et al. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 3739-3744
100. Van Vugt, M.J. and Van de Winkel, J.G. (2001) Fc receptors. In Encyclopedia of Life Sciences, Nature Publishing Group
101. Leslie, R.G. (2001) Complement receptors. In Encyclopedia of Life Sciences, Nature Publishing Group